Phase 4
N=577
Benzocaine Gel Toothache Dose-Response Study
Toothache
Bottom Line
View on ClinicalTrials.gov: NCT00474175 ↗Enrolled (actual)
577
Serious AEs
0.0%
Results posted
Jan 2012
Primary outcome: Primary: Percentage of Participants With a Response — 70.4; 80.7; 87.3 Percentage of participants — p=<0.001
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 4
- Interventions
- Placebo gel (Drug); benzocaine (Drug)
- Age
- Pediatric, Adult, Older Adult · 12+ yrs
- Sex
- All
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Primary completion
- Dec 2010
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Percentage of Participants With a Response |
70.4; 80.7; 87.3 | <0.001 sig |
| SECONDARY Time to First Confirmed Perceptible Relief |
2.0; 1.4; 1.1 | <0.001 sig |
| SECONDARY Time to Meaningful Relief |
8.5; 4.4; 3.2 | <0.001 sig |
| SECONDARY Duration of Effect |
NA; NA; NA | — |
| SECONDARY Sum of Pain Relief Combined With Pain Intensity Differences (SPRID) Scores |
3.1; 3.4; 3.6; 5.9; 6.4; 6.7 | 0.035 sig |
| SECONDARY Time to Dropping Out Due to Lack of Efficacy or Rescue Medication |
NA; NA; NA | — |
| SECONDARY Pain Relief Combined With Pain Intensity Difference (PRID) Scores |
2.72; 3.25; 3.66; 3.08; 3.56; 3.88 | <0.001 sig |
| SECONDARY Global Satisfaction Assessment |
2.1; 2.5; 2.5 | 0.035 sig |
Summary
To evaluate the efficacy and safety of benzocaine gel products for the relief of toothache and to assess the subject's compliance with proposed label directions.
Eligibility Criteria
Inclusion Criteria
- Males or females at least 12 years of age.
- Presence of spontaneous toothache pain in only one permanent tooth. Toothache pain is due only to an open tooth cavity and only as a result of dental caries, loss of a restoration or tooth fracture.
- To qualify for the study, the subject must have a rating of at least moderate pain on the Dental Pain Scale (DPS) and a score of at least 50 mm on the Visual Analog Scale. To be included in the moderate pain stratum, the subjects must have a rating of moderate pain in the DPS and to be included in the severe pain stratum the subjects must have a rating of severe pain in the DPS.
- Females who are neither pregnant, as verified by a urine-based pregnancy test, nor breast-feeding.
- Female subjects of childbearing potential and those who are post-menopausal for less than 2 years must be using a medically approved method of contraception (i.e., oral, transdermal or implanted contraceptive devices, intrauterine device, diaphragm, condom, abstinence, or surgical sterility).
- Subjects must be reliable, cooperative and of adequate intelligence to read and understand the rating scales and other study instructions.
- Subjects must be able to read, comprehend, and sign the consent form. Minors will provide assent to study participation if age appropriate. Parent/legal guardian must be able to read, comprehend, and sign the informed consent form.
Exclusion Criteria
- Presence of spontaneous toothache pain in a primary tooth. Presence of spontaneous toothache pain in more than one tooth. Presence of an open tooth cavity in a tooth adjacent to the painful tooth with the open tooth cavity.
- Presence of concomitant oral pain due to any other condition such as: soft-tissue lesions (e.g., aphthous or traumatic ulcer, herpes labialis, acute necrotizing ulcerative gingivitis); or multiple hard-tissue (e.g., carious) lesions; pain due to other surgical procedures, injuries or dental surface sensitivity.
- Presence of a periodontal abscess as diagnosed from an X-ray or clinical examination of the painful tooth.
- Presence of glucose-6-phosphate dehydrogenase (G6PD) deficiency.
- History of acute or chronic hemolytic anemia.
- History of sensitivity or allergy to benzocaine or other local anesthetic agents.
- Use of any short-acting oral or topical analgesic/ anesthetic product within 2 hours of enrollment or any long-acting Rx or OTC analgesic product within 4 hours of enrollment.
- Use of an investigational drug or participation in an investigational study within the past 30 days.
- Previous participation in this study.
- Member or a relative of the study site staff or sponsor directly involved in the study.
Data sourced from ClinicalTrials.gov (NCT00474175). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.